BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,735,361 | -16.4% | 45,982 | +0.9% | 0.02% | -15.8% |
| Q2 2023 | $2,076,534 | +14.8% | 45,578 | +2.2% | 0.02% | 0.0% |
| Q1 2023 | $1,809,503 | -20.4% | 44,613 | 0.0% | 0.02% | -24.0% |
| Q4 2022 | $2,273,925 | -14.9% | 44,613 | -10.1% | 0.02% | -16.7% |
| Q3 2022 | $2,673,000 | -28.7% | 49,633 | -14.9% | 0.03% | -16.7% |
| Q2 2022 | $3,748,000 | -37.5% | 58,347 | -24.5% | 0.04% | -5.3% |
| Q1 2022 | $5,994,000 | -20.5% | 77,296 | -12.0% | 0.04% | -9.5% |
| Q4 2021 | $7,541,000 | +0.7% | 87,851 | -5.7% | 0.04% | -4.5% |
| Q3 2021 | $7,492,000 | -0.5% | 93,144 | -0.4% | 0.04% | -4.3% |
| Q2 2021 | $7,527,000 | +6.5% | 93,507 | +11.6% | 0.05% | -9.8% |
| Q1 2021 | $7,069,000 | +2.9% | 83,819 | -2.1% | 0.05% | +6.2% |
| Q4 2020 | $6,871,000 | -3.2% | 85,629 | -3.0% | 0.05% | -17.2% |
| Q3 2020 | $7,097,000 | +0.8% | 88,248 | +7.9% | 0.06% | -17.1% |
| Q2 2020 | $7,044,000 | +63.5% | 81,815 | +54.2% | 0.07% | -4.1% |
| Q1 2020 | $4,307,000 | -55.0% | 53,051 | -53.6% | 0.07% | +2.8% |
| Q4 2019 | $9,566,000 | -32.5% | 114,399 | -29.4% | 0.07% | -48.2% |
| Q3 2019 | $14,171,000 | -2.0% | 162,010 | -8.2% | 0.14% | +8.7% |
| Q2 2019 | $14,456,000 | -7.7% | 176,502 | -8.4% | 0.13% | -9.4% |
| Q1 2019 | $15,661,000 | +61.0% | 192,608 | +30.3% | 0.14% | +59.8% |
| Q4 2018 | $9,730,000 | -36.1% | 147,835 | -25.1% | 0.09% | -46.0% |
| Q3 2018 | $15,221,000 | +8.0% | 197,440 | +3.4% | 0.16% | +29.8% |
| Q2 2018 | $14,096,000 | +17.5% | 190,905 | +3.5% | 0.12% | +36.3% |
| Q1 2018 | $11,999,000 | -8.9% | 184,492 | -9.4% | 0.09% | -2.2% |
| Q4 2017 | $13,166,000 | +6.0% | 203,685 | +2.9% | 0.09% | -3.1% |
| Q3 2017 | $12,417,000 | +14.7% | 197,888 | +10.7% | 0.10% | +11.6% |
| Q2 2017 | $10,825,000 | +3.4% | 178,806 | -11.4% | 0.09% | +3.6% |
| Q1 2017 | $10,471,000 | -16.5% | 201,905 | -28.6% | 0.08% | -24.5% |
| Q4 2016 | $12,540,000 | +22.1% | 282,804 | +31.1% | 0.11% | +5.8% |
| Q3 2016 | $10,271,000 | -20.4% | 215,770 | -24.4% | 0.10% | -8.0% |
| Q2 2016 | $12,899,000 | +20.7% | 285,251 | +9.7% | 0.11% | +11.9% |
| Q1 2016 | $10,684,000 | +8.2% | 260,083 | +0.5% | 0.10% | +6.3% |
| Q4 2015 | $9,876,000 | +114.9% | 258,881 | +85.0% | 0.10% | +102.1% |
| Q3 2015 | $4,596,000 | -76.2% | 139,898 | -49.4% | 0.05% | -58.8% |
| Q2 2015 | $19,339,000 | -49.0% | 276,547 | -50.0% | 0.11% | -46.2% |
| Q1 2015 | $37,922,000 | -5.3% | 553,607 | +1.3% | 0.21% | +9.8% |
| Q4 2014 | $40,034,000 | +45.6% | 546,242 | +42.6% | 0.19% | +43.0% |
| Q3 2014 | $27,488,000 | -5.8% | 382,996 | -5.1% | 0.14% | -1.5% |
| Q2 2014 | $29,165,000 | -0.5% | 403,392 | +1.2% | 0.14% | -4.9% |
| Q1 2014 | $29,326,000 | -13.3% | 398,570 | -18.0% | 0.14% | -7.1% |
| Q4 2013 | $33,808,000 | +1.2% | 486,105 | -4.4% | 0.16% | -6.6% |
| Q3 2013 | $33,396,000 | -16.9% | 508,394 | -12.4% | 0.17% | -14.9% |
| Q2 2013 | $40,189,000 | +31.4% | 580,182 | +37.8% | 0.20% | -22.6% |
| Q1 2013 | $30,592,000 | +6.7% | 421,145 | -2.1% | 0.25% | -8.4% |
| Q4 2012 | $28,677,000 | +3.2% | 430,192 | -6.7% | 0.28% | +7.0% |
| Q3 2012 | $27,775,000 | +5.4% | 460,850 | -7.1% | 0.26% | -3.0% |
| Q2 2012 | $26,362,000 | -5.9% | 495,986 | +5.9% | 0.26% | -3.6% |
| Q1 2012 | $28,010,000 | +32.8% | 468,544 | +9.9% | 0.28% | +12.7% |
| Q4 2011 | $21,093,000 | -24.4% | 426,291 | -14.2% | 0.24% | -33.7% |
| Q3 2011 | $27,903,000 | – | 497,022 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |